Entropy Neurodynamics (ASX:ENP) announced a pivotal breakthrough in its TRP-8803 clinical programme, demonstrating repeatable psychedelic effects in its ongoing binge eating disorder trial.
The company confirmed that the third patient in Cohort 1 completed their scheduled IV-infused psilocin treatments on April 9, with all participants to date achieving the desired psychedelic response.
Clinicians reported the ability to replicate the onset, depth, and duration of these effects, highlighting the precision-controlled nature of the two-phase intravenous regimen.
The reproducibility is a cornerstone of the programme's IP, protected by a recently granted Australian patent extending to 2042, which allows for rapid onset and the unique ability to terminate treatment immediately by halting the infusion.
The trial, which integrates drug administration with supportive therapy, is nearing the completion of its first mid-range dose cohort, while enrolment for Cohort 2 is already well advanced.
Beyond clinical milestones, the company’s financial position has been bolstered by a $1.7 million R&D tax incentive refund from the Australian Government, bringing its cash reserves to over $6.4 million.
The funds are earmarked for the continued development of TRP-8803 and a proprietary EEG-based "brain entropy" biomarker platform developed in collaboration with Imperial College London.
At the time of reporting, Entropy Neurodynamics’ share price was $0.029.